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decrease in the glomerular filtration rate would 
constitute clinical tumor lysis syndrome (see 
Table 1 of our article). Removal of a 25% change 
from the definition by Cairo and Bishop applies 
only to uric acid, phosphorus, potassium, and 
calcium. The lack of randomized studies pre-
cludes definitive recommendation of a specific 
diuretic. For now, the rat model provides the 
only available data, and furosemide has proved 
effective in our practice.
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Fiberoptic Intubation
To the Editor: In his video on fiberoptic intuba-
tion (May 19 issue),1 Heidegger provides excellent 
points for patients with a known or suspected 
difficult airway. Some readers may infer that 
there is a single way of preparing the patient and 
performing a fiberoptic intubation, yet multiple 
methods may be used for these procedures. The 
sizes of the endotracheal tube and the fiberoptic 
scope can vary according to several clinical fac-
tors (e.g., a smaller tube for suspected airway 
edema or subglottic narrowing). Also, I would 
suggest that it is preferable to have the patient in 
a sitting position with the laryngoscopist facing 
the patient, since this position optimizes airway 
anatomy. To prepare the patient, local anesthetics 
other than cocaine (e.g., lidocaine and tetracaine) 
are routinely used, and other vasoconstrictors 
(e.g., phenylephrine and oxymetazoline) can mini-
mize the risk of intranasal bleeding. The admin-
istration of intravenous fentanyl (at a dose of 2 μg 
per kilogram of body weight) may be hazardous 
to some patients, and sedation often is not re-
quired or not safe. The intratracheal injection of 
local anesthetic is not necessary in many patients 
and, in those with a tenuous airway, could result 
in violent coughing and loss of the airway.
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To the Editor: In patients who are undergoing 
fiberoptic intubation, we believe that it is essen-
tial to distinguish between awake and asleep 
techniques. The indications for an awake proce-
dure, as presented by Heidegger, are too broad 
and, as described, might put the patient in un-
necessary danger. Poor dentition, a beard, or obe-
sity are not common indications for awake fiber-
optic intubation and reflect what we consider to 
be an outdated approach to the management of a 
difficult airway. According to our practice, awake 
fiberoptic intubation is appropriate only when 
the patient is at risk for being in a “cannot intu-
bate, cannot ventilate” situation (e.g., in cases of 
stridor secondary to airway cancer or neck 
mass).1 The primary objective is to maintain pa-
tency of the upper airway until it is secured by 
the orotracheal tube. To avoid oversedation and 
upper-airway obstruction, any long-acting drug, 
such as clonidine or fentanyl, which may produce 
an alteration of consciousness, should not be 
used, especially not in combination. In our judg-
ment, an ultrashort-acting opioid, such as remi-
fentanil, which overcomes this problem, is pref-
erable.2
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAETSBIBLIOTHEK BERN on December 3, 2018. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 365;6 nejm.org august 11, 2011 575
Eric Albrecht, M.D. 
Patrick Schoettker, M.D.
Centre Hospitalier Universitaire Vaudois 
Lausanne, Switzerland 
eric.albrecht74@gmail.com
No potential conflict of interest relevant to this letter was re-
ported.
1. Practice guidelines for management of the difficult airway: 
an updated report by the American Society of Anesthesiologists 
Task Force on Management of the Difficult Airway. Anesthesiol-
ogy 2003;98:1269-77. [Erratum, Anesthesiology 2004;101:565.]
2. Puchner W, Egger P, Pühringer F, Löckinger A, Obwegeser J, 
Gombotz H. Evaluation of remifentanil as single drug for awake 
fiberoptic intubation. Acta Anaesthesiol Scand 2002;46:350-4.
To the Editor: The video on fiberoptic intuba-
tion provides a thorough illustration and narra-
tive of the fiberoptic-intubation technique. How-
ever, we feel that certain issues bear discussion. 
The author recommends oxygen insufflation 
through the bronchoscope during intubation to 
assist with atomization of local anesthetic. This 
practice is unnecessary and should be avoided in 
small children and patients with airway edema, 
since the egress of gas around the bronchoscope 
may be impaired, thereby increasing the risk of 
pneumothorax.1
The administration of a hypnotic before ad-
vancement of the tracheal tube is suggested as a 
method for performing fiberoptic intubation 
without patient discomfort. In our experience, 
most patients have no discomfort with tracheal-
tube placement after effective topical anesthe-
sia. Furthermore, the rationale for performing 
fiberoptic intubation while the patient is awake 
is usually based on concern about difficulty with 
ventilation. If a hypnotic is administered and 
tracheal-tube placement is difficult (e.g., the 
tube hangs up at the glottis or esophageal in-
tubation occurs), a situation may arise in which 
the airway is unsecured and ventilation is im-
possible.
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The author replies: As stated in the video and 
in the accompanying supplementary text (and as 
correctly addressed by Bennett-Guerrero and 
Stolp), there are different ways to prepare the 
patient and perform fiberoptic intubation. The 
choice of equipment is primarily dependent on 
personal preference and local circumstance. 
Whether fiberoptic intubation should be per-
formed in the sitting position is also primarily 
dependent on the physician who performs the 
procedure. However, from my experience, it is very 
important to perform the procedure as you nor-
mally would, especially in difficult situations. 
The combination of oral clonidine and 2 μg per 
kilogram of intravenous fentanyl normally has 
only a mild and desired sedative effect. However, 
as mentioned in the article, no sedating medica-
tion should be given to patients with a severely 
compromised airway, not even during insertion 
of the fiberscope.
Reducing the indication of awake fiberoptic 
intubation to patients who are at risk for a “can-
not intubate, cannot ventilate” situation, as rec-
ommended by Albrecht and Schoettker, is poten-
tially dangerous and against common sense and 
established practice (“Daily practice is the key to 
success in emergencies”). It is well known that 
the common appearance of more risk factors is a 
strong predictor of difficult mask ventilation.1,2 
A recent survey that was based on data from 
nearly 2.9 million patients who underwent gen-
eral anesthesia in the United Kingdom showed 
that obese patients are at increased risk for an 
obstructed airway because of difficult mask ven-
tilation, difficult intubation, or both.3 In an edi-
torial on the survey results, the authors con-
cluded that “obesity must now be regarded as a 
significant material risk in airway management” 
and called for the development of evidence-based 
algorithms for airway management in patients 
who were at high risk for difficult intubation.4 
I am convinced that fiberoptic intubation will 
play an important part in such cases.
The comments by Fiadjoe and Stricker regard-
ing oxygen insufflation in small children are 
helpful. Continuous oxygen should be applied 
very carefully in adults as well. It is particularly 
dangerous if the bronchoscope is unintention-
ally advanced into the esophagus, which might 
lead to rupture of the stomach because of over-
insufflation.
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In daily practice, the concept of fiberoptic 
intubation in the awake patient is not clearly 
defined. In most cases, the choice of technique 
is dependent on institutional and personal pref-
erences. Ultimately, such a choice is a compro-
mise between safety, practicability, and accep-
tance. The technique as shown in the video is a 
thoroughly documented, well-tested method that 
has not been changed for many years.5
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Deferoxamine for Advanced Hepatocellular Carcinoma
To the Editor: We have previously reported that 
the iron chelator deferoxamine can prevent liver 
injury as well as the development of preneoplas-
tic lesions in rats,1,2 and we have proposed the 
use of deferoxamine as an anticancer drug. The 
antiproliferative effect of deferoxamine arrests 
the cell cycle and induces apoptosis.3 To our 
knowledge, no clinical study has been performed 
to evaluate deferoxamine therapy in patients with 
hepatocellular carcinoma.4
Our study involved 10 patients (6 men and 
4 women) who had advanced hepatocellular carci-
noma and did not have a response to hepatic arte-
rial infusion chemotherapy with anticancer drugs. 
The average age of the patients was 64 years 
(range, 43 to 77). Written informed consent was 
obtained before the study, which was approved 
by the institutional review board of Yamaguchi 
University Hospital. Seven patients had hepati-
tis C virus infection, 2 patients had hepatitis B 
virus infection, and 1 patient did not have either 
type of infection. The tumor stages were classi-
fied as II, IVA, and IVB (according to the Liver 
Cancer Study Group of Japan criteria) for 1, 2, and 
7 patients, respectively. The Child–Pugh class was 
A, B, and C for 3, 5, and 2 patients, respectively. 
(In the Child–Pugh classification of liver disease, 
class A indicates the least severe disease, class B 
moderately severe disease, and class C the most 
severe disease.) The patients received an arterial 
infusion of deferoxamine (at a dose of 10 to 80 
mg per kilogram of body weight) over 24 hours 
on alternate days, through the injection port.
Deferoxamine was administered an average of 
27 times (range, 9 to 78). Two, three, and five pa-
tients had a partial response, stable disease, and 
progressive disease, respectively (according to the 
Eastern Cooperative Oncology Group criteria). 
The overall response rate was 20%.
Tumor-marker levels (alpha-fetoprotein, des-γ-
carboxyprothrombin, alpha-fetoprotein L3, or all 
of these levels) decreased in patients with a par-
tial response. In one patient, a massive hepato-
cellular tumor with lung metastases disappeared 
with deferoxamine treatment (Fig. 1). The 1-year 
cumulative survival rate was 20%. Four patients 
had grade 2 or 3 interstitial pneumonia (accord-
ing to the Common Terminology Criteria for 
Adverse Events, version 4.0), and one patient had 
grade 2 renal dysfunction. However, no grade 4 
adverse events were observed.
Sorafenib, a multikinase inhibitor, has recently 
been established as the standard of care for pa-
tients with advanced hepatocellular carcinoma 
and preserved liver function (Child–Pugh class A) 
because it increases survival.5 However, its safety 
and efficacy for patients with Child–Pugh class 
B or C disease is still unknown. Deferoxamine 
may warrant testing in patients with Child–Pugh 
class B or C hepatocellular carcinoma.
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